Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00175058 · ClinicalTrials.gov registry record · Phase 3
Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)
A Phase 3 study, sponsored by TherOx.
- Completed
- Registry status
- Phase 3
- Development phase
- 317
- Enrollment target
NCT00175058 is a Phase 3 study that has completed, run by TherOx. The registered enrollment target is 317 participants.
The verdict
NCT00175058, a Phase 3 study, has completed, sponsored by TherOx.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 317 participants
- Enrollment target
Study Summary
To determine whether or not HyperOxemic therapy rendered to patients (that meet the study inclusion criteria) with anterior acute myocardial infarction \< 6 hours from symptom onset to reperfusion, results in a significant reduction in infarct size as measured by SPECT @ 14 days post event.
Interventions
- DEVICE AO Therapy (aqueous oxygen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00175058
The ClinicalTrials.gov registry entry for NCT00175058 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TherOx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AO Therapy (aqueous oxygen) is the first listed.
NCT00175058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00175058 about?
NCT00175058 is a clinical study titled "Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)". To determine whether or not HyperOxemic therapy rendered to patients (that meet the study inclusion criteria) with anterior acute myocardial infarction \< 6 hours from symptom onset to reperfusion, results in a significant reduction in infarct size as measured by SPECT @ 14 days post event.
What is the current status of trial NCT00175058?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 317 participants. The study started on 2005-08. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00175058?
The interventions under investigation include: AO Therapy (aqueous oxygen) (DEVICE).
Who is sponsoring clinical trial NCT00175058?
This trial is sponsored by TherOx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.